Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung.

Underwood DC, Osborn RR, Bochnowicz S, Webb EF, Rieman DJ, Lee JC, Romanic AM, Adams JL, Hay DW, Griswold DE.

Am J Physiol Lung Cell Mol Physiol. 2000 Nov;279(5):L895-902.

2.

Differences in time-related cardiopulmonary responses to hypoxia in three rat strains.

Bochnowicz S, Osborn RR, Luttmann MA, Louden C, Hart T, Hay DW, Underwood DC.

Clin Exp Hypertens. 2000 Jul;22(5):471-92.

PMID:
10937839
3.

SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence.

Underwood DC, Osborn RR, Kotzer CJ, Adams JL, Lee JC, Webb EF, Carpenter DC, Bochnowicz S, Thomas HC, Hay DW, Griswold DE.

J Pharmacol Exp Ther. 2000 Apr;293(1):281-8.

PMID:
10734180
4.

Effect of SB 217242 on hypoxia-induced cardiopulmonary changes in the high altitude-sensitive rat.

Underwood DC, Bochnowicz S, Osborn RR, Luttmann MA, Louden CS, Hart TK, Elliott JD, Hay DW.

Pulm Pharmacol Ther. 1999;12(1):13-26.

PMID:
10208832
5.

Antiasthmatic activity of the second-generation phosphodiesterase 4 (PDE4) inhibitor SB 207499 (Ariflo) in the guinea pig.

Underwood DC, Bochnowicz S, Osborn RR, Kotzer CJ, Luttmann MA, Hay DW, Gorycki PD, Christensen SB, Torphy TJ.

J Pharmacol Exp Ther. 1998 Dec;287(3):988-95.

PMID:
9864284
6.

Chronic hypoxia-induced cardiopulmonary changes in three rat strains: inhibition by the endothelin receptor antagonist SB 217242.

Underwood DC, Bochnowicz S, Osborn RR, Louden CS, Hart TK, Ohlstein EH, Hay DW.

J Cardiovasc Pharmacol. 1998;31 Suppl 1:S453-5.

PMID:
9595510
7.

1,4-Cyclohexanecarboxylates: potent and selective inhibitors of phosophodiesterase 4 for the treatment of asthma.

Christensen SB, Guider A, Forster CJ, Gleason JG, Bender PE, Karpinski JM, DeWolf WE Jr, Barnette MS, Underwood DC, Griswold DE, Cieslinski LB, Burman M, Bochnowicz S, Osborn RR, Manning CD, Grous M, Hillegas LM, Bartus JO, Ryan MD, Eggleston DS, Haltiwanger RC, Torphy TJ.

J Med Chem. 1998 Mar 12;41(6):821-35.

PMID:
9526558
8.
9.

Hypoxia-induced pulmonary hypertension in an optimized environment for the guineapig.

Bochnowicz S, Osborn RR, Hay DW, Underwood DC.

Lab Anim. 1997 Oct;31(4):347-56.

PMID:
9350706
10.

The influence of endogenous catecholamines on the inhibitory effects of rolipram against early- and late-phase response to antigen in the guinea pig.

Underwood DC, Matthews JK, Osborn RR, Bochnowicz S, Torphy TJ.

J Pharmacol Exp Ther. 1997 Jan;280(1):210-9.

PMID:
8996198
11.

Catecholamine and beta-adrenoceptor influences on airway reactivity to antigen in guinea pigs.

Underwood DC, Matthews JK, Osborn RR, Novak LB, Bochnowicz S, Meunier LD.

Int Arch Allergy Immunol. 1996 Mar;109(3):286-94.

PMID:
8620099
12.

Dose-dependent mediation of leukotriene D4-induced airway microvascular leakage and bronchoconstriction in the guinea pig.

Bochnowicz S, Underwood DC.

Prostaglandins Leukot Essent Fatty Acids. 1995 Jun;52(6):403-11.

PMID:
7644563
13.

Comparison of phosphodiesterase III, IV and dual III/IV inhibitors on bronchospasm and pulmonary eosinophil influx in guinea pigs.

Underwood DC, Kotzer CJ, Bochnowicz S, Osborn RR, Luttmann MA, Hay DW, Torphy TJ.

J Pharmacol Exp Ther. 1994 Jul;270(1):250-9.

PMID:
8035322

Supplemental Content

Loading ...
Support Center